Skip to main content

Table 9 Baseline characteristics of patients with HAM/TSP who had been observed for four years (n = 148)

From: Real-world clinical course of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Japan

  All patients
(n = 148)
Steroid (S) group
(n = 47)
Steroid-
history
(SH) group
(n = 36)
Untreated (U) group
(n = 32)
Miscella-
neous (M) group
(n = 33)
p value Groups with significant difference c)
Sex: Female 112
(75.7%)
36
(76.6%)
25
(69.4%)
24
(75.0%)
27
(81.8%)
0.690 a)
Age at baseline (year)d 61.8 ± 9.7 63.0 ± 7.5 61.4 ± 9.7 60.6 ± 12.4 61.5 ± 9.7 0.740 b)
Age at onset (year)d 43.4 ± 14.4 47.5 ± 13.0 40.5 ± 15.2 42.2 ± 13.1 41.7 ± 15.7 0.113 b)
Disease durationd (Time from onset to initial interview) 17.5 ± 10.4 15.7 ± 9.4 19.8 ± 10.0 16.6 ± 10.6 18.3 ± 11.9 0.300 b)
Baseline OMDSd 5.8 ± 2.2 6.0 ± 2.3 6.6 ± 2.4 4.8 ± 1.4 5.7 ± 2.1 0.012 b) SH > U
Rapid progressorse 21 (14.2%) 10 (21.3%) 5 (13.9%) 3 (9.4%) 3 (9.1%) 0.354 a)
  1. Statistical methods: a) By chi-square test, b) By analysis of variance, c) By Tukey post hoc tests
  2. dData are expressed as mean ± standard deviation, e Rapid progressors were defined as those who developed OMDS 5 or above within 2 years from the onset of motor symptoms. Abbreviation: OMDS, Osame motor disability score